(Q30738419)

26 June 2017

Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected]. (English)

1 reference

26 June 2017

1 reference

1 reference

7

David M Doddrell

1 reference

26 June 2017

David G Carey

1

1 reference

26 June 2017

Gary J Cowin

2

1 reference

26 June 2017

Graham J Galloway

3

1 reference

26 June 2017

Nigel P Jones

4

1 reference

26 June 2017

Jackie C Richards

5

1 reference

26 June 2017

Nandita Biswas

6

1 reference

26 June 2017

1 October 2002

1 reference

26 June 2017

1 reference

26 June 2017

10

1 reference

26 June 2017

1008-1015

1 reference

26 June 2017

10

1 reference

Metabolic implications of body fat distribution

26 June 2017

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.137

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.137

Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.137

Fatty livers and reduced adipose tissue, who wants it?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.137

The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.137

Insulin resistance and obesity. The role of fat distribution pattern

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.137

Separate associations between visceral and subcutaneous adipose tissue distribution, insulin and glucose levels in obese women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.137

Relationships of generalized and regional adiposity to insulin sensitivity in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.137

Abdominal fat and insulin resistance in normal and overweight women: Direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.137

Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.137

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.137

Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.137

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.137

Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.137

Comparison of adipose tissue changes following administration of rosiglitazone in the dog and rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.137

A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.137

Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.137

Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.137

Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.137

Adipose tissue distribution and plasma lipoprotein levels in obese women. Importance of intra-abdominal fat

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.137

Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.137

Non-alcoholic steatohepatitis: another disease of affluence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.137

Measurement of liver fat by MRI and its reduction by dexfenfluramine in NIDDM

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.137

Fast adipose tissue (FAT) assessment by MRI

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.137

Sex differences in lean and adipose tissue distribution by magnetic resonance imaging: anthropometric relationships

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.137

Quantification of liver fat using magnetic resonance spectroscopy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.137

Effect of troglitazone on body fat distribution in type 2 diabetic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.137

Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FOBY.2002.137

31 March 2020

Identifiers

DOI

10.1038/OBY.2002.137

1 reference

26 June 2017

1 reference